Cardiovascular Abnormalities in Late Onset Pompe Disease and Response to Enzyme Replacement Therapy

Abstract

Purpose

We evaluated the prevalence of cardiovascular abnormalities and the efficacy and safety of enzyme replacement therapy (ERT) in patients with late onset Pompe disease.

Methods

Ninety patients were randomized 2:1 to ERT or placebo in a double-blind protocol. Electrocardiograms (ECG) and echocardiograms were obtained at baseline and scheduled intervals over the 78-week study period. Baseline cardiovascular abnormalities, and efficacy and safety of ERT were described. Three pediatric patients were excluded.

Results

Eighty-seven patients were included. Median age was 44 years; 51% were male. At baseline, a short PR interval was present in 10%, 7% had decreased left ventricular systolic function, and 5% had elevated left ventricular mass on echocardiogram (all in mild range). There was no change in cardiovascular status associated with ERT. No significant safety concerns related to ERT were identified.

Conclusions

Although some patients with late onset Pompe disease had abnormalities on baseline ECG or echocardiogram, those classically seen in infantile Pompe disease, such as significant ventricular hypertrophy, were not noted. Cardiovascular parameters were not impacted by ERT and there were no cardiovascular safety concerns. The cardiovascular abnormalities identified may be related to Pompe disease or other comorbid conditions.

INTRODUCTION

Pompe disease (glycogen storage disease type II; OMIM # 232300) is an autosomal recessive disease caused by a deficiency in the lysosomal enzyme acid alpha-glucosidase. This enzyme defect impacts an estimated 1:40,000 live births and results in an accumulation of glycogen in tissues throughout the body including smooth, skeletal, and cardiac muscle (1,2). There is a wide spectrum of disease severity dependant on the level of residual enzyme activity. Classic infantile Pompe disease is characterized by residual enzyme activity of < 1% and progressive hypotonia, hypertrophic cardiomyopathy, hepatomegaly, and respiratory insufficiency typically leading to death within the first year of life without enzyme replacement therapy (3,4). In contrast, late onset Pompe disease (juvenile and adult) is caused by a partial deficiency of acid alpha-glucosidase and has a more insidious course (5–8). Typical symptoms in this form of the disease consist of slowly progressive proximal muscle weakness and respiratory difficulties (9–11). Previous studies have suggested that a smaller proportion of patients with late onset Pompe disease (< 10%) have cardiovascular involvement, including electrophysiological abnormalities and myocardial hypertrophy (12–14).

Current treatment for Pompe disease consists of enzyme replacement therapy with Chinese hamster ovary cell (CHO) derived recombinant human acid alpha-glucosidase. Infants have shown significant reduction in left ventricular mass, improvement in cardiac function, and reversal of electrocardiographic abnormalities following enzyme replacement therapy (15–23). Studies have also demonstrated stabilization/improvement in both respiratory and motor symptoms in patients with late onset Pompe disease (24–27). No studies to date have examined response of cardiovascular abnormalities to enzyme replacement therapy in late onset Pompe patients.

The purpose of this analysis was to describe the cardiovascular abnormalities present at baseline in patients with late onset Pompe disease, and to evaluate the effects of enzyme replacement therapy on cardiovascular efficacy and safety parameters.

MATERIALS & METHODS

Study Design

This study was a post-hoc analysis of cardiovascular parameters in a double-blind, multi-center, randomized controlled trial evaluating the efficacy and safety of acid alpha-glucosidase enzyme replacement therapy versus placebo in patients with late onset Pompe disease. The primary efficacy endpoints of the original trial consisted of the six minute walk test and the percent-predicted forced vital capacity in the upright position (ClinicalTrial.Gov identifier #NCT00158600; Protocol No. AGLU02704). Results of the primary analysis have been recently published (28). The present analysis focuses on evaluation of cardiovascular endpoints. This study was approved by the Institutional Review Board/Ethics Committee at each primary site, and all patients provided informed consent.

Patient Population and Randomization

Patients ≥ 8 years of age with a diagnosis of Pompe disease based on deficient endogenous acid alpha-glucosidase activity in cultured skin fibroblasts of ≤ 40% of the normal mean of the testing laboratory and 2 or more acid alpha-glucosidase gene mutations were eligible for inclusion (28). Inclusion criteria included the ability to ambulate 40 meters on each six minute walk test performed on 2 consecutive days (use of assistive devices such as a walker, cane, or crutches was permitted), the ability to perform pulmonary function testing, and a forced vital capacity of ≥ 30% and < 80% predicted in the upright position. A negative pregnancy test was also required for females of reproductive age. Exclusion criteria consisted of the following: previous exposure to acid alpha-glucosidase, current requirement for invasive ventilatory support or any ventilatory support while awake and in an upright position, exposure to other investigational therapies in the last 30 days, and major congenital anomalies or history of other medical conditions that may significantly interfere with study compliance.

Ninety patients were randomized 2:1 to the treatment arm using a minimization algorithm in an effort to balance the groups for disease severity (29). Groups were stratified according to baseline six minute walk test with a threshold of 300 meters and baseline upright forced vital capacity with a threshold of 55% of the predicted value.

Study Interventions and Data Collection

The treatment arm received bi-weekly infusions of enzyme replacement therapy at a dose of 20 mg/kg for the 78 week study period, and the control group received a volume matched placebo infusion. Enzyme replacement therapy consisted of Chinese hamster ovary cell derived recombinant human acid alpha-glucosidase.

Demographic parameters including age, gender and race/ethnicity were obtained at baseline. Data on disease duration was also obtained and was defined as the number of years since symptom onset. All study electrocardiograms (ECG) and echocardiograms were performed at one of the eight principal study sites (see Appendix A). A 12-lead ECG was obtained at baseline and at 26, 52, and 78 weeks. All ECG’s were interpreted at the central cardiology core lab by a cardiologist blinded to treatment arm. Rate, rhythm, intervals, axes, and voltages were evaluated in the usual manner and normal thresholds were determined by accepted adult normative ranges. Tachycardia was defined as > 100 beats per minute and bradycardia as < 55 beats per minute. A short PR interval was defined as a PR interval ≤ 120 milliseconds. Prolonged QRS duration was defined as > 120 milliseconds. The corrected QT interval was calculated using Bazett’s formula, and normal defined as < 440 milliseconds for males and < 450 milliseconds for females. Ventricular hypertrophy and atrial enlargement were defined using standard adult criteria (30). Specifically, left ventricular hypertrophy on ECG was defined using a combination of the Sokolow-Lyon and Cornell criteria.

Echocardiographic evaluation of left ventricular size and function was performed at baseline, 52 and 78 weeks. All echocardiograms were interpreted at the central cardiology core lab by a cardiologist blinded to treatment allocation. Left ventricular ejection fraction was calculated from two dimensional images using the modified Simpson’s rule in all patients. Abnormal ejection fraction was defined as < 55% (31). Left ventricular mass was evaluated using two-dimensional (2D) echocardiography and the truncated ellipsoid method (31). If the two-dimensional image quality was not sufficient, M-mode assessment was performed and left ventricular mass was calculated using the American Society of Echocardiography method (31). All left ventricular mass measurements were indexed to body surface area to calculate left ventricular mass index. American Society of Echocardiography guidelines were used to define normal and abnormal ranges for left ventricular mass index (31). For females, elevated left ventricular mass index was defined as > 88 g/m² for two-dimensional measurements, or > 95 g/m² for M-mode measurements. For males, elevated left ventricular mass index was defined as > 102 g/m² for two-dimensional measurements or > 115 g/m² for M-mode measurements (31).

Statistical Analysis

Study variables were described using standard summary statistics. Categorical variables were expressed as frequencies and percentages and continuous variables as medians and inter-quartile range. Demographic data at baseline were described in the overall cohort of patients, and compared in the treatment and control groups using the Wilcoxon rank sum and Fisher’s exact test where appropriate. Similarly, cardiovascular status (including ECG and echocardiographic data) was described at baseline in the overall cohort of patients and compared in those with a disease duration < 15 years vs. ≥ 15 years. A duration of 15 years was chosen as this was the median duration of illness for the cohort. To determine cardiovascular efficacy of therapy, we evaluated the change from baseline to 78 weeks in ECG and echocardiographic parameters in the treatment and control groups. Only those patients with data points both at baseline and at 78 weeks were included in the efficacy analysis. For continuous variables, change from baseline in the control and treatment groups was compared using the Wilcoxon rank sum test. For dichotomous variables, logistic regression was utilized to assess status at 78 weeks, controlling for baseline status and treatment group. Finally, cardiovascular safety was evaluated by comparing the proportion of patients who developed any ECG or echocardiographic abnormalities at any time during the study period that were not present at baseline in the treatment and control groups using Fisher’s exact test. All analyses were conducted using STATA version 10 (College Station, TX). Reported p-values are two-tailed, and a p-value < 0.05 was considered statistically significant.

RESULTS

Patient Characteristics

Of 108 patients screened, 90 were randomized: 60 to the treatment arm and 30 to the control arm. We excluded three patients < 17 years of age from the analysis as the ECG and echocardiography normative ranges utilized are only applicable to the adult population. Thus, 87 patients were included in the present analysis. Patient characteristics overall, and in each treatment arm, are displayed in Table 1. Age, gender, race, and disease duration were similar in the treatment and placebo groups.

Table 1.

Patient characteristics

	Control (n=28)	ERT (n=59)	Overall (n=87)	p-value
Age (years)	44 [40,51]	45 [38,53]	44 [39,52]	0.56
Gender, male	11 (39%)	33 (56%)	44 (51%)	0.17
Race/ethnicity				0.52
Caucasian	26 (93%)	56 (95%)	82 (94%)
Asian	0 (0%)	1 (2%)	1 (2%)
Hispanic	1 (4%)	1 (2%)	2 (2%)
Black	1 (4%)	0	1 (1%)
Mixed	0	1 (2%)	1 (1%)
Disease duration (years)	16 [11,23]	15 [9,20]	15 [10,21]	0.20

Data presented are n (%) for categorical variables and median [interquartile range] for continuous variables.

ERT= enzyme replacement therapy

Baseline Cardiovascular Status

Table 2 displays baseline ECG and echocardiographic data for the entire cohort. At baseline, 84 patients (97%) had an ECG performed, and 85 patients (98%) had an echocardiogram performed measuring left ventricular ejection fraction. Seventy-four patients (85%) had an echocardiogram of sufficient quality to determine left ventricular mass index. Overall, 46% of patients had one or more of the ECG or echocardiographic abnormalities listed in Table 2 at baseline. On echocardiogram, 4 patients overall (5%) had an elevated left ventricular mass index, all of which were in the mild range (3 females, range 92 – 97gm/m²; 1 male, 104 gm/m²). Six patients (7%) had a left ventricular ejection fraction less than 55% (range 41–54%). There was no overlap between the group with elevated left ventricular mass index and the group with decreased ejection fraction. The most common abnormalities seen on ECG were left ventricular hypertrophy in 12% and a short PR interval in 10% (range 90 –120 ms). Of note, in the 10 patients (12%) with left ventricular hypertrophy on ECG, only one had elevated left ventricular mass index on echocardiography (although two others did not have a baseline echocardiogram). Of the 4 patients (5%) with an elevated left ventricular mass index on echocardiogram, only one had left ventricular hypertrophy on ECG.

Table 2.

Baseline cardiovascular status

	Overall	Disease Duration <15 Years (n=43)	Disease Duration ≥ 15 Years (n=42)	p-value
Echo Data
Ejection fraction	61 [57,63]	61 [58,64]	61 [57,63]	0.51
Ejection fraction <55%	6 (7%)	3 (7%)	3 (7%)	0.99
2D LVMI (g/m2)	71 [61,80]	72 [61,79]	71 [60,82]	0.93
Elevated LVMI	4 (5%)	3 (8%)	1 (3%)	0.35
M-mode LVMI (g/m2)	60 [51,68]	65 [57,71]	51 [50,60]	0.09
Elevated LVMI	0 (0%)	0 (0%)	0 (0%)	--
ECG Data
Rhythm
Sinus	78 (93%)	37 (88%)	41 (98%)	0.20
Sinus tachycardia	5 (6%)	5 (12%)	0 (0%)	0.06
Ectopic atrial	1 (1%)	0 (0%)	1 (2%)	0.99
Heart rate (bpm)	74 [65,83]	71 [65,88]	75 [65,80]	0.67
PR interval (ms)	153 [140,160]	155 [140,160]	150 [140,167]	0.48
Short PR	8 (10%)	5 (12%)	3 (7%)	0.71
Atrioventricular block	0 (0%)	0 (0%)	0 (0%)	--
QRS duration (ms)	83 [80,90]	83 [80,90]	83 [80,90]	0.81
Prolonged QRS	1 (1%)	0 (0%)	1 (2%)	0.99
QTc interval (ms)	398 [386,414]	400 [386,413]	396 [386,414]	0.89
Prolonged QTc	3 (4%)	1 (2%)	2 (5%)	0.99
Right bundle branch block	1 (1%)	0 (0%)	1 (2%)	0.99
Left bundle branch block	1 (1%)	0 (0%)	1 (2%)	0.99
Incomplete bundle branch block	2 (2%)	1 (2%)	1 (2%)	0.99
Right atrial enlargement	1 (1%)	1 (2%)	0 (0%)	0.99
Left atrial enlargement	3 (3%)	1 (2%)	2 (5%)	0.99
Right ventricular hypertrophy	0 (0%)	0 (0%)	0 (0%)	--
Left ventricular hypertrophy	10 (12%)	4 (10%)	6 (14%)	0.74
Supraventricular Ectopy
PAC	0 (0%)	0 (0%)	0 (0%)	--
SVT	0 (0%)	0 (0%)	0 (0%)	--
Ventricular Ectopy
PVC	0 (0%)	0 (0%)	0 (0%)	--
Ventricular Tachycardia	0 (0%)	0 (0%)	0 (0%)	--
WPW	2 (2%)	2 (5%)	0 (0%)	0.16

Data presented are n (%) for categorical variables and median [interquartile range] for continuous variables.

LVMI = Left ventricular mass index, RBBB= right bundle branch block, LBBB= left bundle branch block, PAC = premature atrial contraction, SVT = supraventricular tachycardia, PVC = premature ventricular contraction, WPW = Wolfe-Parkinson-White syndrome.

84 patients had ECG data and 85 patients had ejection fraction data on echocardiogram. For left ventricular mass index, 61 patients had 2D and 13 patients had M-mode data.

Table 2 also displays the proportion of patients with cardiovascular abnormalities according to disease duration. There were no significant differences seen in those with disease duration < 15 years vs. ≥ 15 years. Of note, in the patients who developed symptoms before 10 years of age, three (60%) had one or more ECG or echocardiographic abnormalities.

Follow-up

Five (8%) patients in the enzyme replacement therapy group and four (14%) patients in the placebo group did not complete the study. Reasons for not completing the study in the treatment group included the following: hypersensitivity reactions related to the study medication (2), death unrelated to treatment (1), and switch to commercial enzyme replacement therapy (2). In the control group, the reasons included: adverse event not related to study medication (1), switch to commercial enzyme replacement therapy (1), and missed 78-week study appointments (2). No events leading to discontinuation of the study were related to the cardiovascular system.

Efficacy of Enzyme Replacement Therapy

Table 3 displays ECG and echocardiographic data at baseline and 78 weeks in the treatment and placebo arms for those who completed the study. Of patients with baseline ECG data, 89% had follow-up ECG data. Of patients with baseline echocardiographic data, 80% had follow up echocardiographic data. No significant changes in ECG or echocardiographic parameters were seen in association with enzyme replacement therapy compared with placebo.

Table 3.

Efficacy of enzyme replacement therapy.

	Control Baseline	Control 78 Weeks	Change	ERT Baseline	ERT 78 Weeks	Change	p-value
Echo Data
Ejection fraction	57 [56,61]	58 [56,60]	−1 [−2,3]	61 [58,63]	61 [58,64]	0 [−2,3]	0.80
Ejection fraction <55%	2 (11%)	3 (16%)		3 (6%)	4 (8%)		0.44
Elevated LVMI	1 (6%)	1 (6%)		2 (4%)	4 (9%)		0.71
ECG Data
PR Interval (ms)	160 [140,160]	150 [140,180]	0 [−10,20]	150 [140,160]	150 [140,163]	0 [−10,10]	0.71
Short PR	1 (5%)	3 (14%)		6 (11%)	4 (8%)		0.14
QRS duration (ms)	82 [70,90]	90 [80,100]	7 [0,17]	87 [80,90]	90 [87,100]	5 [0,10]	0.67
Prolonged QRS	1 (5%)	1 (5%)		0 (0)	1 (2%)		0.53
QTc Interval (ms)	400 [387,417]	406 [396,420]	20 [−5,28]	398 [386,413]	413 [404,428]	16 [−1,27]	0.99
Prolonged QTc	0 (0%)	3 (14%)		3 (6%)	7 (13%)		0.85
Left ventricular hypertrophy	3 (14%)	2 (9%)		6 (11%)	5 (9%)		0.72

Data presented are n (%) for categorical variables and median [interquartile range] for continuous variables.

ERT = enzyme replacement therapy, Elevated LVMI = Elevated left ventricular mass index by either 2-dimensional or M-mode measurements. 19 control patients and 49 ERT patients had baseline and 78 week ejection fraction data;16 control patients and 43 ERT patients had baseline and 78 week LMVI data;22 control patients and 53 ERT patients had baseline and 78 week ECG data.

Cardiovascular Safety of Enzyme Replacement Therapy

Table 4 displays data on the proportion of patients with an ECG and echocardiographic abnormality at any time during the study period which was not present at baseline. There were no significant differences between the treatment and placebo groups. Of note, a 40 year old male in the treatment arm with a known history of Wolff-Parkinson-White syndrome and recurrent episodes of supraventricular tachycardia experienced an episode of supraventricular tachycardia 8 days after the week 6 treatment. This patient had normal left ventricular mass index and ejection fraction at baseline. He was admitted to the hospital and successfully converted to sinus rhythm. The Data Safety Monitoring Board classified this event as serious and possibly related to the study medication. This patient continued in the trial until 23 weeks into the study when he left to pursue commercial treatment. Another patient in the treatment group with a history of Wolff-Parkinson-White syndrome with a concealed pathway did not experience arrhythmias during the study. An additional patient in the enzyme replacement arm had new multiple premature ventricular contractions and sinus tachycardia (103 beats per minute) on the 52-week ECG that normalized on subsequent ECGs. This was not classified as a clinically significant adverse event. This patient had a normal ejection fraction and left ventricular mass index at baseline and normal ejection fraction on the 52-week echocardiogram (measurements of left ventricular mass were not obtained on the 52-week echocardiogram).

Table 4.

New onset cardiovascular abnormalities during the study period

	Control	ERT	p-value
Echo Data
Ejection fraction <55%	3 (13%)	5 (10%)	0.70
ECG Data
Rhythm
Sinus bradycardia	2 (7%)	3 (5%)	0.66
Sinus tachycardia	0 (0%)	4 (7%)	0.30
Atrioventricular block	0 (0%)	0 (0%)	--
Prolonged QRS duration	1 (4%)	2 (4%)	0.99
Prolonged QTc interval	3 (11%)	7 (13%)	0.99
Bundle Branch Block	1 (4%)	2 (4%)	0.99
Supraventricular Ectopy
PAC	1 (4%)	1 (2%)	0.54
SVT	0 (0%)	1 (2%)	0.99
Ventricular Ectopy
PVC	0 (0%)	1 (2%)	0.99
Ventricular Tachycardia	0 (0%)	0 (0%)	--

ERT = enzyme replacement therapy, PAC = premature atrial contraction, SVT = supraventricular tachycardia, PVC = premature ventricular contraction. Percentages based on the number of patients who did not have the abnormality at baseline.

DISCUSSION

This is the first analysis to evaluate cardiovascular response to enzyme replacement therapy in patients with late onset Pompe disease. While some patients had abnormalities identified on ECG or echocardiogram at baseline, those such as severe ventricular hypertrophy classically associated with the infantile form of Pompe disease were not noted There was no significant change in cardiovascular status over the 78 week study period, and no significant cardiovascular safety concerns associated with enzyme replacement.

The most common abnormalities identified on baseline testing in our cohort were left ventricular hypertrophy (12%) and short PR interval on ECG (10%), and decreased ejection fraction on echocardiogram (7%). Only 5% of patients had elevated left ventricular mass index on echocardiogram, and these values were all in the mild range. These findings are in contrast to those described in infantile Pompe disease where ECG abnormalities are universal and cardiac hypertrophy on echocardiogram is much more prevalent and severe (3,4,32). In late onset Pompe disease, a previous study of 38 patients found a similar proportion of patients with a short PR interval (8%) compared to our study, however did not observe any ventricular hypertrophy (13). Other studies have also reported a smaller proportion with left ventricular hypertrophy in comparison to our findings (12,14). For example, in a study of 68 late onset Pompe patients, there were only 2 patients with abnormal ECG and echocardiographic findings that could not sufficiently be explained by other causes and were potentially related to Pompe disease (12). Likely explanations for these differences may include the smaller patient population in previous studies, potential differences in normative criteria and techniques of assessment of left ventricular hypertrophy, or differences in the proportion of patients with other conditions such as hypertension and other factors which may also impact left ventricular size (12–14). Data from our study suggest that left ventricular hypertrophy as assessed by ECG is not specific for the diagnosis of increased left ventricular mass in patients with late onset Pompe disease. Detailed information regarding hypertension and other co-morbidities was not collected in the present study precluding further analysis to ascertain the potential relationship of such factors to the cardiac abnormalities identified.

The underlying pathogenesis of the left ventricular hypertrophy seen in patients with infantile Pompe disease is thought to be related to intracellular glycogen accumulation leading to cellular hypertrophy (15,33). There is often both cardiac hypertrophy and decreased systolic function present which can prompt the clinician to consider infiltrative processes such as Pompe disease as opposed to hypertrophic cardiomyopathy. There are limited data regarding late onset Pompe disease. A single previous autopsy report has shown intracardiac glycogen accumulation, although to a much lesser degree than that seen in the infantile form of the disease (34). It is hypothesized that glycogen accumulation and left ventricular hypertrophy is less pronounced and much more rare in late onset Pompe disease due to the presence of residual alpha-glucosidase activity (7).

Wolff-Parkinson-White syndrome and a shortened PR interval are commonly seen in patients with both infantile and late onset Pompe disease (12,13,32,35–37). These are thought to be related to disruption of the annulus fibrosis (which normally electrically separates the atria and ventricles and routes conduction through the atrioventricular node) by glycogen-filled myocytes allowing ventricular pre-excitation, and disruption of the normal conduction delay through the atrioventricular node (38,39). Other cardiovascular abnormalities seen in our study include bundle branch block (4%) and atrial enlargement (4%). Bundle branch block could be related to glycogen-laden cells affecting the Bundle of His. Atrial enlargement may be a product of poor ventricular compliance and diastolic dysfunction due to glycogen deposition and ventricular hypertrophy. Diastolic dysfunction has been demonstrated in a previous study of patients with late onset Pompe disease (14). Alternatively, these findings may be unrelated to Pompe disease. For example, in the general population, the prevalence of bundle branch block is approximately 2.5% in the 25–74 year age range (40).

There was no significant change in echocardiographic or ECG parameters seen in our study in the enzyme replacement group vs. placebo over the 78 week study period. In contrast, in the infantile form of the disease, normalization of the PR interval and reduction in left ventricular hypertrophy following enzyme replacement therapy have been shown to occur (15,20,32,38,39). Given the mild cardiac abnormalities identified at baseline in our study, a significant change with enzyme replacement therapy may not be expected. In addition, we would not expect to see a response in those subjects whose ECG or echocardiographic abnormalities are due to other comorbidities and not related to Pompe disease. Alternatively, it is possible that late onset Pompe patients, who are often not diagnosed until later in life may already have entered the necrotic/fibrotic phase, which may not be reversible with enzyme replacement therapy (15,20,21,32,41). It could also be possible that the treatment duration in this study may not have been long enough to effect change in certain cardiovascular parameters. The effect of enzyme replacement therapy on general muscle and respiratory function has been shown to occur gradually over a three year period in patients with late onset Pompe disease (24).

There were no significant cardiovascular safety concerns associated with enzyme replacement. No difference in cardiac adverse events was seen in patients receiving enzyme replacement therapy vs. placebo. Significant ventricular ectopy has been reported previously in patients with infantile Pompe disease undergoing enzyme replacement therapy in two studies with a prevalence of 17% and 18% respectively (42,43). In our study, there was one patient in the treatment arm with ventricular ectopy; however, this consisted of infrequent, asymptomatic, isolated premature ventricular complexes on one ECG which resolved on follow-up. The only cardiac adverse event deemed to be “serious” in this trial was an episode of supraventricular tachycardia in the patient with Wolff-Parkinson-White syndrome that required hospital admission. However, this patient had a history of multiple episodes of supraventricular tachycardia, and it was unclear if this episode was related to enzyme replacement therapy.

Limitations

There are several limitations to this analysis. First, not every patient had an ECG or echocardiogram performed at each time point. Thus, our analysis was limited to those with complete baseline and follow-up data. In addition, assessment of left ventricular mass was undertaken with two different echocardiographic techniques. We did not assess changes in diastolic function in this study, and imaging was limited to echocardiography. Although this is the largest study of enzyme replacement in patients with late onset Pompe disease to date, the relatively small sample size may have limited our ability to detect small differences between groups. Furthermore, the 78 week treatment duration precludes our ability to detect longer term changes. Finally, we were not able to account for the presence of other comorbidities in our analysis of left ventricular size and function as these data were not available.

Conclusions

While some patients with late onset Pompe disease had abnormalities on ECG or echocardiogram at baseline, cardiovascular abnormalities such as severe ventricular hypertrophy classically associated with the infantile form of Pompe disease were not noted. There were no significant changes in cardiovascular status following 78 weeks of enzyme replacement therapy, and we did not identify significant safety concerns. The cardiovascular abnormalities we identified may be related to Pompe disease or other co-morbid conditions, and their clinical significance should be determined in consultation with the patient’s primary physician. Longer-term evaluation of enzyme replacement therapy in a larger cohort of late onset Pompe patients will be needed to further evaluate baseline characteristics of the multiple Pompe genotypes, co-morbidities, additional risk factors, progression of disease, and potential response to long-term enzyme replacement therapy.

APPENDIX A

The eight primary investigational sites included

University of Pittsburgh (Pennsylvania)

Children’s National Medical Center (Washington D.C.)

Tower Hematology Oncology Group (California)

Washington University (Missouri)

Mount Sinai Medical Center (New York)

Hôpital de la Pitié-Salpétrière, Institut de Myologie (France)

Erasmus Medical Center (The Netherlands)

Sophia Children’s Hospital (The Netherlands)

Late Onset Treatment Study Principle Site Investigators

Paula Clemens MD (University of Pittsburgh), Diana M. Escolar MD (Children’s National Medical Center), Robert T. Leshner (Children’s National Medical Center), Pascal Laforêt MD (Institut de Myologie), Alan Pestronk MD (Washington University), Melissa Wasserstein MD (Mount Sinai School of Medicine), Ans van der Ploeg MD PhD (Sophia Children’s Hospital, Erasmus Medical Center), Barry Rosenbloom MD (Mount Sinai Medical Center).

Late Onset Treatment Study Transfer Site Investigators

Edward Culper MD (Oregon Health and Science University), Eugen Mengel MD (Kinderklinik der Universität Mainz), Robert Hopkin MD (Cincinnati Children’s Hospital Medical Center), Robin Casey MD (Alberta Children’s Hospital), Joel Charrow MD (Children’s Memorial Hospital), David Sillence MD (Children’s Hospital at Westmead), Bernard Lemieux MD (Centre Hospitalier Universitaire de Sherbrooke), Katherine Sims MD (Massachusetts General Hospital), C. Ronald Scott MD (University of Washington Medical Center), Isablle Durieu MD (Centre Hospitalier Lyon Sud), Alain Furby MD (Hôpital Yves Le Foll), Fabien Zagnoli MD (H.I.A. Clermont Tonnerre), Richard Barohn MD (Kansas University Medical Center), Sharon Nations MD (Southwestern Medical Center of Dallas), Reed Pyeritz MD PhD (University of Pennsylvannia School of Medicine), Terence Edgar MD (Prevea Pediatric Neurology), Bruce Barship MD PhD (University of California, San Diego), Mark Olsen MD (Oklahoma Oncology & Hematology, P.C.), James Tita DO (St. Vincent Mercy Medical Center), G. Bradley Schaefer MD (University of Nebraska Medical Center), Kirk Aleck MD (St Joseph’s Hospital and Medical Center).